N-[2-(2-thiophene)ethyl]-N'-[2-(5-bromopyridyl)]-thiourea | 258340-15-7

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 吡啶及其衍生物
• 英文名称: N-[2-(2-thiophene)ethyl]-N'-[2-(5-bromopyridyl)]-thiourea
• 英文别名: 1-(5-bromopyridin-2-yl)-3-(2-thiophen-2-ylethyl)thiourea；N'-[2-(2-tiophene)ethyl]-N'-[2-(5-bromopyridyl)]thiourea；N-[2-(2-thiophene)ethyl]-N'-[2-(5-bromopyridyl)]thiourea；1-[2-(2-thiophene)ethyl]-3-[2-(5-bromopyridyl)]thiourea；DDE-443；HI-443
• CAS: 258340-15-7
• 化学式: C₁₂H₁₂BrN₃S₂
• 分子量: 342.283
• InChiKey: GAIBJCKASOWHGH-UHFFFAOYSA-N

物化性质

• 熔点：
  160-161 °C
• 沸点：
  445.3±55.0 °C(Predicted)
• 密度：
  1.589±0.06 g/cm3(Predicted)

计算性质

• 辛醇/水分配系数(LogP)：
  3.2
• 重原子数：
  18
• 可旋转键数：
  4
• 环数：
  2.0
• sp3杂化的碳原子比例：
  0.17
• 拓扑面积：
  97.3
• 氢给体数：
  2
• 氢受体数：
  3

反应信息

• 作为产物：
  描述：

  噻吩乙胺 、 imidazole-1-carbothionic acid (5-bromopyridin-2-yl)amide 以 N,N-二甲基甲酰胺 为溶剂， 反应 18.0h， 以75.2%的产率得到N-[2-(2-thiophene)ethyl]-N'-[2-(5-bromopyridyl)]-thiourea
  参考文献：
  名称：

  DuMez, Darin; Venkatachalam, Taracad K.; Uckun, Fatih M., Arzneimittel-Forschung/Drug Research, 2007, vol. 57, # 6, p. 330 - 338

  摘要：

  DOI：

文献信息

• Non-nucleoside reverse transcriptase inhibitors
  申请人：Kennedy-Smith Joshua

  公开号：US20080045511A1

  公开（公告）日：2008-02-21

  The present invention provides for compounds useful for treating an HIV infection, or preventing an HIV infection, or treating AIDS or ARC. The compounds of the invention are of formula I wherein A is A1, A2, A3 or A4 and R 1 , R 2 , R 3 , R 4a , R 4b , R 5 , R 6 , Ar, X 1 , X 2 , X 4 , X 4 and X 5 are as herein defined. Also disclosed in the present invention are methods of treating an HIV infection with compounds defined herein and pharmaceutical compositions containing said compounds.

  本发明提供了用于治疗HIV感染、预防HIV感染、治疗艾滋病或AIDS相关复合征（ARC）的有用化合物。本发明的化合物具有式I的结构，其中A为A1、A2、A3或A4，且R1、R2、R3、R4a、R4b、R5、R6、Ar、X1、X2、X4、X4和X5如本文所定义。本发明还公开了使用本文定义的化合物治疗HIV感染的方法以及含有这些化合物的药物组合物。
• [EN] DERIVATIVES AND COMPOSITION OF QUINOLINE AND NAPHTHYRIDINE<br/>[FR] DÉRIVÉS ET COMPOSITION DE QUINOLÉINE ET DE NAPHTYRIDINE
  申请人：CHULABHORN FOUND

  公开号：WO2019045655A1

  公开（公告）日：2019-03-07

  Provided is compound of formula (I) where: X and Y may be identical or different and represent O, NH, or S; R 1, R 2, R 3, R 4, R 5, R 6, R 7, R 8, R 9, and R 10 may be identical or different and represent H, halogen, CN, NO 2, (C 1-4)alkyl, (C 1-4)haloalkyl, (C 2-4)alkenyl, OH, O(C 1-4)alkyl, O(C 1-4)haloalkyl, N(R A)R B, C(O)N(R A)R B, C(O)R A, CO 2R A, CHO, C 2-4alkenyl substituted with CN, C 2-4alkenyl substituted with COOH, C 2-4alkenyl substituted with CHO, or C 2-4alkenyl substituted with OH; R A and R B may be identical or different and represent H, (C 1-4)alkyl, (C 1-4)haloalkyl, or (C 2-4)alkenyl; A 1, A 2, A 3, and A 4 may be identical or different and represent CH or N with the proviso that A 1 and A 2 cannot be N and that R 5 and R 10 are absent when A 3 and A 4 are N; or a pharmaceutically acceptable salt thereof, stereoisomer thereof, or mixture comprising stereoisomers thereof.

  提供的是化合物的结构式（I），其中：X和Y可以相同也可以不同，代表O、NH或S；R1、R2、R3、R4、R5、R6、R7、R8、R9和R10可以相同也可以不同，代表H、卤素、CN、NO2、（C1-4）烷基、（C1-4）卤代烷基、（C2-4）烯基、OH、O（C1-4）烷基、O（C1-4）卤代烷基、N（RA）RB、C（O）N（RA）RB、C（O）RA、CO2RA、CHO、C2-4烯基被CN取代、C2-4烯基被COOH取代、C2-4烯基被CHO取代，或C2-4烯基被OH取代；RA和RB可以相同也可以不同，代表H、（C1-4）烷基、（C1-4）卤代烷基或（C2-4）烯基；A1、A2、A3和A4可以相同也可以不同，代表CH或N，但A1和A2不能同时为N，且当A3和A4为N时，R5和R10不存在；或其药用盐、立体异构体或包含立体异构体的混合物。
• NON-NUCLEOSIDE REVERSE TRANSCRIPTASE INHIBITORS
  申请人：Kennedy-Smith Joshua

  公开号：US20110059975A1

  公开（公告）日：2011-03-10

  The present invention provides for compounds useful for treating an HIV infection, or preventing an HIV infection, or treating AIDS or ARC. The compounds of the invention are of formula I wherein A is A2 and R 1 , R 2 , R 3 , R 4a , R 4b , R 5 , R 6 , Ar, X 1 , X 2 , X 4 , X 4 and X 5 are as herein defined. Also disclosed in the present invention are methods of treating an HIV infection with compounds defined herein and pharmaceutical compositions containing said compounds.

  本发明提供了一种用于治疗HIV感染、预防HIV感染或治疗艾滋病或ARC的化合物。本发明的化合物的公式为I，其中A为A2，R1、R2、R3、R4a、R4b、R5、R6、Ar、X1、X2、X4、X4和X5如本文所定义。本发明还揭示了使用上述化合物治疗HIV感染的方法和包含该化合物的药物组合物。
• N′-[2-(2-thiophene)ethyl]-N′-[2-(5-bromopyridyl)] thiourea as a potent inhibitor of nni-resistant and multidrug-resistant human immunodeficiency virus-1
  作者：Fatih M. Uckun、Sharon Pendergrass、Danielle Maher、Dan Zhu、Lisa Tuel-Ahlgren、Chen Mao、T.K. Venkatachalam

  DOI：10.1016/s0960-894x(99)00624-1

  日期：1999.12

  The thiophene-ethyl thiourea (TET) compound N'-[2-(2-thiophene)ethyl]-N'-[2-(5-bromopyridl)]-thiourea (compound HI-443) was five times more potent than trovirdine, 1250 times more potent than nevirapine, 100 times more potent than delavirdine, 75 times more potent than MKC-442, and 50 times more potent than AZT against the multidrug resistant HIV-1 strain RT-MDR with a V106A mutation. HI-443 was almost as potent against the NNI-resistant HIV-I strain A17 with a Y181C mutation as it was against HTLVIIIB. The activity of HI-443 against A17 was ten times more potent than that of trovirdine, 2083 times more potent than that of nevirapine, and 1042 times more potent than that of delavirdine. HI-443 inhibited the replication of the NNI-resistant HIV-1 strain A17 variant with Y181C plus K103N mutations in RT with an IC, value of 3.3 mu M, whereas the IC50 values of trovirdine, nevirapine, and delavirdine were all >100 mu M. These findings establish the novel thiophene containing thiourea compound HI-443 as a novel NNI with potent antiviral activity against NNI-sensitive, NNI-resistant and multidrug-resistant strains of HIV-l. (C) 1999 Elsevier Science Ltd. All rights reserved.
• Uckun, Fatih M.; Erbeck, Douglas; Tibbles, Heather, Arzneimittel-Forschung/Drug Research, 2007, vol. 57, # 3, p. 164 - 170
  作者：Uckun, Fatih M.、Erbeck, Douglas、Tibbles, Heather、Qazi, Sanjive、Venkatachalam, Taracad K.

  DOI：——

  日期：——